A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: A systematic review

International Journal of Geriatric Psychiatry

Volumn 29, Issue 6, 2014, Pages 551-561

  Davison, Christopher M ^a   O'Brien, John T ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

dementia; mild cognitive impairment; PET; positron emission tomography; single photon emission computed tomography; SPECT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; COMPARATIVE STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; FRONTOTEMPORAL DEMENTIA; HUMAN; LEWY BODY; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; DEGENERATIVE DISEASE; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; PROCEDURES; SCINTISCANNING;

DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84899969765     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4036     Document Type: Review

References (69)

1. Albert MS, DeKosky S, Dickson D, et al,. 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement 7 (3): 270-279.
2. Berti V, Pupi A, Mosconi L,. 2011. PET/CT in diagnosis of dementia. Ann N Y Acad Sci 1228: 81-92.
3. Bloudek L, Spackman D, Blankenburg M, Sullivan S,. 2011. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimer's Dis 26 (4): 627-645.
4. Bohnen N, Djang D, Herholz K, Anzai Y, Minoshima S,. 2012. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med 53: 59-71.
5. Bonte F, Wiener M, Bigio E, White CL,. 1997. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 202 (3): 793-7.
6. Bonte F, Harris M, Hynan L, Bigio E, White C,. 2006. Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation. Clin Nucl Med 31 (7): 376-8.
7. Colloby S, O'Brien J,. 2004. Functional Imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17: 158-163.
8. Colloby S, Taylor J, Firbank M,. 2010. Covariance 99mTc-exametazime SPECT patterns in Alzheimer's disease and dementia with Lewy bodies: utility in differential diagnosis. J Geriat Psych Neurology 23 (1): 54-62.
9. Devous M,. 2002. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med 29: 1685-1695.
10. Dobert N, Pantel J, Frolich L, et al,. 2005. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord 20 (2-3): 63-70.
11. Dougall N, Bruggink S, Ebmeier K,. 2004. Systematic review of the diagnostic accuracy of Tc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12: 554-570.
12. Dubois B, Feldman H, Jacova C, et al,. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 6: 734-46.
13. Dubois B, Feldman HH, Jacova C, et al,. 2010. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9 (11): 1118-1127.
14. Ebmeier K,. 2010. Is there still a place for perfusion SPECT in the diagnosis of dementia? Open Nuc Med J 2: 40-45.
15. Foster N, Heidebrink J, Clark C, et al,. 2007. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130: 2616-2635.
16. Gemmell H, Evans N, Besson J, et al,. 1990. Regional cerebral blood flow imaging: a quantitative comparison of technetium-99m-HMPAO SPECT with C15O2 PET. J Nucl Med 31 (10): 1595-1600.
17. Habert MO, Horn JF, Sarazin M, et al,. 2011. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiol aging 32 (1): 15-23.
18. Hanyu H, Shimizu S, Hirao K, et al,. 2006. Differentiation of dementia with Lewy bodies from Alzheimer's disease using Mini-Mental State Examination and brain perfusion SPECT. J Neurol Sci 250: 97-102.
19. Herholz K,. 2011. Perfusion SPECT and FDG-PET. Int Psychogeriatr 23 (Supplement 2): S25-S31.
20. Herholz K, Schopphoff H, Schmidt M, et al,. 2002. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer disease. J Nucl Med 43: 21-26.
21. Herholz K, Carter S, Jones M,. 2007. Positron emission tomography in dementia. Brit J of Radiology 80: S160-167.
22. Herholz K, Westwood S, Haense C, Dunn G,. 2011. Evaluation of a calibrated 18F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 52 (8): 1218-1226.
23. Higuchi M, Tashiro M, Arai H, et al,. 2000. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 162: 247-256.
24. Hoffman J, Welsh-Bohmer K, Hanson M, et al,. 2000. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41: 1920-1928.
25. Hort J, O'Brien JT, Gainotti G, et al,. 2010. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17: 1236-1248.
26. Ishii K, Minoshima S,. 2005. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease-for. Eur J Nucl Med Mol Imaging 32: 1463-1466.
27. Ishii K, Imamwa T, Sasaki M, et al,. 1998. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 51: 125-130.
28. Ishii K, Masahiro S, Sakamoto S, et al,. 1999. Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy- d -glucose PET in Alzheimer's disease. Comparison of perfusion and metabolic patterns. Clin Nucl Med 24 (8): 572-575.
29. Ishii K, Hosaka K, Mori T, Mori E,. 2004. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Annals Nucl Med 18 (5): 447-451.
30. Jack C, Albert M, Knopman D, et al,. 2011. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262.
31. Jagust W, Thisted R, Devous M, et al,. 2001. SPECT perfusion imaging in the diagnosis of Alzheimer's disease. Neurology 56: 950-956.
32. Jagust W, Reed B, Mungas D, Ellis W, Decarli C,. 2007. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69: 871-877.
33. Jobst K, Hindley N, King E, Smith A,. 1994. The diagnosis of Alzheimer's disease: a question of image? J Clin Psychiatry 55: 22-31.
34. Kemp P, Holmes C,. 2007. Imaging in dementia with Lewy bodies: a review. Nuc Med Comm 28: 511-519.
35. Knopman D, DeKosky S, Cummings J, et al,. 2001. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. 56 (9): 1143-1153.
36. Kuwabara Y, Ichiya Y, Otsuka M, et al,. 1990. Comparison of I-123 IMP and Tc-99m HMPAO SPECT studies with PET in dementia. Ann Nucl Med 4 (3): 75-82.
37. Landau S, Harvey D, Madison C, et al,. 2010. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 73 (3): 230-238.
38. Lim S, Katsifis A, Villemagne V, et al,. 2009. The 18F-FDG PET cingulate island sign and comparison to 123I-b-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50: 1638-1645.
39. Lobotesis K, Fenwick J, Phipps A, et al,. 2001. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56: 643-649.
40. Lucignani G, Nobili F,. 2010. FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough? Eur J Nucl Med Mol Imaging 37: 1604-1609.
41. McKeith I, Galasko D, Kosaka K, et al,. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (5): 1113-1124.
42. McKeith IG, Dickson DW, Lowe J, et al,. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65: 1863-1972.
43. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (7): 939-944.
44. McKhann G, Knopman D, Chertkov H, et al,. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269.
45. McMahon P, Araki S, Sandberg E, Neumann P, Gazelle G,. 2003. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228: 515-522.
46. McNeill R, Sare G, Manoharan M, et al,. 2007. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. J Neurol Neurosurg Psychiatry 78: 350-355.
47. Messa C, Perani D, Lucignani G, et al,. 1994. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. J Nucl Med 35: 210-216.
48. Mielke R, Pietrzyk U, Jacobs A, et al,. 1994. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 21: 1052-1060.
49. Minoshima S, Foster NL, Sima AAF, et al,. 2001. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50: 358-265.
50. Mosconi L, Tsui W, Herholz K, et al,. 2008. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49: 390-398.
51. N.I.C.E. 2006. Dementia. Supporting people with dementia and their carers in health and social care. Clinical Guideline Number 42. National Institute for Health and Clinical Excellence: London.
52. Neary D, Snowden JS, Gustafson L, et al,. 1998. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51: 1546-1554.
53. Nihashi T, Yatsuya H, Hayasaka K, et al,. 2007. Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat Med 25: 255-262.
54. Nobili F, De Carli F, Frisoni GB, et al,. 2009. SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment. J Alzheimers Dis 17 (4): 761-772.
55. Panegyres P, Rogers J, McCarthy M, Campbell A, Wu J,. 2009. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol 9: 41-50.
56. Patwardhan M, McCrory D, Matchar D, Samsa G, Rutschmann O,. 2004. Alzheimer disease: operating characteristics of PET-a meta-analysis. Radiology 231: 73-80.
57. Pimlott S, Ebmeier K,. 2007. SPECT imaging in dementia. Brit J Radiol 80: S153-159.
58. Pupi A, Nobili F,. 2005. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease-against. Eur J Nucl Med Mol Imaging 32: 1466-72.
59. Quigley H, Colloby S, O'Brien JT,. 2011. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 26: 991-999.
60. Roman G, Tatemichi T, Erkinjuntti T, et al,. 1993. Vascular dementia: diagnostic criteria for research studies. Neurology 43: 250-260.
61. Shimizu S, Hanyu H, Kanetaka H, et al,. 2005. Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. Dement Geriatr Cogn Disord 20: 25-30.
62. Silverman D,. 2004. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45 (4): 594-607.
63. Silverman D, Small G, Chang C, et al,. 2001. Positron emission tomography in evaluation of dementia. JAMA 286: 2120-2127.
64. Silverman D, Gambhir S, Huang H, et al,. 2002. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 43: 253-266.
65. Sinha N, Firbank M, O'Brien J,. 2011. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry 27 (5): 443-453.
66. Sperling RA, Aisen PS, Beckett LA, et al,. 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (3): 280-292.
67. Talbot P, Lloyd JJ, Snowden J, Neary D, Testa H,. 1998. A clinical role for 99mTC HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 64: 306-313.
68. Toney L, MsCue T, Minoshima S, Lewis D,. 2011. Nuclear medicine imaging in dementia: a practical overview for hospitalists. Hosp Pract 39 (3): 149-160.
69. Yuan Y, Gu Z, Wei W,. 2009. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR Imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. Am J Neuroradiol 30 (2): 404-410.